Login
Open Demat Account
Open Demat A/C
Offerings
+
Research
Markets+
Talking Finance+
Support+
Media+
Partner Us+
Trade LoginReports LoginIFD Partner Login
Demo
Close Language Tab
Locate us
Languages
Home Market News and Insights Details
News

Zydus Lifesciences gets USFDA Nod for Ibrutinib tablets

24-Jul-2025 | 13:16
Zydus Lifesciences informed that it has received tentative approval from the United States Food and Drug Administration (USFDA) for Ibrutinib tablets 140 mg, 280 mg, and 420 mg.

Ibrutinib is a kinase inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) with a 17p deletion, and Waldenstr?m's macroglobulinemia (WM).

Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. The tablets had annual sales of $2,148.9 million in the United States (IQVIA MAT May 2025).

The group now holds 420 approvals and has filed a total of 484 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company?s consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24.

Shares of Zydus Lifesciences rose 0.78% to currently trade at Rs 969.15 on the BSE.

Powered by Capital Market - Live News